GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanmi Pharm Co Ltd (XKRX:128940) » Definitions » Price-to-Owner-Earnings

Hanmi Pharm Co (XKRX:128940) Price-to-Owner-Earnings : 50.48 (As of Jun. 01, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Hanmi Pharm Co Price-to-Owner-Earnings?

As of today (2025-06-01), Hanmi Pharm Co's share price is ₩311500.00. Hanmi Pharm Co's Owner Earnings per Share (TTM) ended in Mar. 2025 was ₩6170.90. It's Price-to-Owner-Earnings for today is 50.48.


The historical rank and industry rank for Hanmi Pharm Co's Price-to-Owner-Earnings or its related term are showing as below:

XKRX:128940' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.13   Med: 38.75   Max: 1280.39
Current: 49.59

During the past 13 years, the highest Price-to-Owner-Earnings of Hanmi Pharm Co was 1280.39. The lowest was 8.13. And the median was 38.75.


XKRX:128940's Price-to-Owner-Earnings is ranked worse than
76.12% of 448 companies
in the Drug Manufacturers industry
Industry Median: 25.175 vs XKRX:128940: 49.59

As of today (2025-06-01), Hanmi Pharm Co's share price is ₩311500.00. Hanmi Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩8,591.00. Therefore, Hanmi Pharm Co's PE Ratio (TTM) for today is 36.26.

As of today (2025-06-01), Hanmi Pharm Co's share price is ₩311500.00. Hanmi Pharm Co's EPS without NRI for the trailing twelve months (TTM) ended in was ₩9,988.84. Therefore, Hanmi Pharm Co's PE Ratio without NRI for today is 31.18.

During the past 13 years, Hanmi Pharm Co's highest PE Ratio without NRI was 817.83. The lowest was 13.96. And the median was 53.53.


Hanmi Pharm Co Price-to-Owner-Earnings Historical Data

The historical data trend for Hanmi Pharm Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanmi Pharm Co Price-to-Owner-Earnings Chart

Hanmi Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 590.74 96.26 27.26 31.18

Hanmi Pharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.05 17.54 24.75 31.18 36.54

Competitive Comparison of Hanmi Pharm Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Hanmi Pharm Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanmi Pharm Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanmi Pharm Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Hanmi Pharm Co's Price-to-Owner-Earnings falls into.


;
;

Hanmi Pharm Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Hanmi Pharm Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=311500.00/6170.90
=50.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hanmi Pharm Co  (XKRX:128940) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Hanmi Pharm Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Hanmi Pharm Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanmi Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
45 Bangi-dong, Songpa, Seoul, Gyeonggi, KOR, 138-724
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.

Hanmi Pharm Co Headlines

No Headlines